#Symptoms of Vascular Dementia

[feminist-space]

Cat in the Hat:

"The German Health Minister gave an important update on the Covid situation yesterday.

I’ve written up the section of his speech from the video below for easy reading.

It’s immensely refreshing to see a government minister warning of the harms of Covid in such a transparent way."

https://x.com/_catinthehat/status/1732092683508678954

Prof. Karl Lauterbach

Health Minister, Germany

4 December 2023

"This second (long Covid) round table was very interesting, lasting three and a half hours. It serves as a unique forum for dialogue among scientists, researchers and those affected by long Covid, facilitating the exchange of ideas.

There are many new findings about long Covid. Not all of them are good news. One piece of not-so-good news concerns the fact that long Covid is actually still a problem for those who are newly infected. One estimate that has been put forward is that the risk of contracting long Covid now, even after vaccination, is around 3%. Now you may say, "that's not such a big risk" , but there are tens of thousands of people who are repeatedly affected in a short period of time. And so, the long Covid problem has not yet been solved.

We have also established that there really are many subgroups of long Covid and that we do not yet have a cure. And it was clearly pointed out that we are also dealing with problems here that will challenge society as a whole, because vascular diseases often occur after long Covid. Throughout Europe, we are currently seeing an increased incidence of cardiovascular disease in the middle-age group - from 25 to 50. This is associated with the consequences of Covid infections.

We also very often find cognitive impairment in older people. And one participant pointed out that it may well be like the Spanish flu, where 20 years after the Spanish flu there was a significant increase in Parkinson's disease and probably also dementia.

This is something we must pay attention to, as the past infection afiects how the immune system in the brain functions, as well as the brain's blood vessels, potentially increasing the long-term risk of these major neurodegenerative diseases. This is why we need to conduct very intensive research. This research has played a major role.

What is the overall assessment of the situation now?

We have to be careful. Long Covid is not curable at the moment. We also know that over 40% of those who have several manifestations of long Covid, for example, five or more, still have symptoms after 2 years, so it doesn't seem to heal spontaneously. We also know that those whose symptoms are more pronounced at the beginning are less likely to heal.

So some of what we know from the demographics of long Covid has been confirmed, and we now know more precisely which mechanisms in the brain, but also in the blood vessels and the immune system, are responsible for this. Professor Scheibenbogan will explain this briefly later.

At this point, I can only say the following - this is particularly important to me:

First of all, long Covid is a disease that stays with us and that we cannot yet cure. And we are seeing an increasing number of cases as the waves of infection continue to affect us.

Secondly, Covid is not a cold - with a cold, you don't usually see any long-term effects. You don't see any changes in the blood vessels. You don't usually see an autoimmune disease developing. You also don't usually see neurological inflammation - these are all things that we see with long Covid. Therefore, one should not assume that Covid infection is just a common cold. It can affect brain tissue and the vascular system, and we still lack an effective treatment, making these studies crucial.

Significantly, we know that the risk of long Covid decreases when you're infected but have been vaccinated. That's why it's concerning that only 3 million people have been vaccinated with the new, adapted vaccine. That is a very bad result.

Please protect yourself from severe infections.

Please protect yourself from long Covid.

Currently, the danger posed by Covid is indeed being underestimated. Nothing is worse than infecting someone at Christmas who then becomes seriously ill and may not fully recover."

Alt text is included in all images of this post.

[nits-wits]

usher genetics

spoilers for the fall of the house of usher below

this might be a symptom of being in medical school but when i realized that to the outside eye and to roderick for a while, verna and all of the supernatural shit is all explained by CADASIL, as the vascular dementia produces hallucinations. for those who don't know CADASIL is a real disease! and it has an autosomal dominant inheritance (cerebral Autosomal Dominant arteriopathy with subcortical Infarcts and leukoencephalopathy). if you don't remember high school genetics, look at this punnet square:

it essentially shows that if a person with the AD disease (Kk - K indicating the diseased allele, k indicating the normal allele) has a child with someone who is unaffected (kk), there's a 50% chance that the child will have the disease.

roderick has CADASIL, as he got it from his mother, and in roderick, it is presenting with what seems to be incredibly vivid horrible hallucinations.

here's the thing though - before they die, all of the usher children ALSO have vivid hallucinations (or rather, verna comes to them) and i was wondering why they are much younger than their dad and presenting with similar symptoms. and then i realized something else was at play. anticipation. in genetics, anticipation occurs when a disease presents earlier and more severely in the following generations. a classic case of this occurs with huntington's disease.

roderick gets it old, but then as he has kids, they get it younger, and lenore, the final generation, has her hallucination as a very young teenager. it took a small literature search to find this case study of a Japanese family with CADASIL that does indeed present with anticipatory genes. it also makes sense that the hallucinations and presentation of all of the children all show up - CADASIL has complete penetrance even if there's clinical variability.

when verna says "let the next generation deal with it", it's not just all of the shit and horror that capitalism and boomers and roderick kick the can down to, but also the very real horror of subjecting children to hallucinations that show their incoming death.

good job @flanaganfilm. this nerd appreciates your commitment to the storytelling.

[landboundstar]

Neurodivergence should be more normalized than it is.

Period.

It should be normalized.

And we need to talk about it more.

We recently - like last 15 years or so- have started talking more about autism and ADHD.

Oh, we have known about it longer. We have talked about it academically.

I mean talking about it over dinner or on our work breaks.

Maybe some people have spoken about it longer, but in the past 15 years, I have seen an increase in that discussion.

Especially as we learn more about autism and ADHD.

But there is more than that.

Psychosomatic symptoms

Situational triggers

Various sensory issues

Neurodivergence from illness and injury and trauma.

They exist. In the past 5 years, I am starting to hear people talking about those too.

But not as much. Not loudly.

Please.

Talk more about it. Talk about symptoms more. Talk about how you cope.

It matters.

It matters when we talk about how to focus our attention. It matters when we talk about stimming, soothing, and other ways to cope. It matters when we talk about grounding techniques. It matters when we talk about our struggles and our adaptations

It matters for mental health. It matters for physical health - I only recently learned about vascular dementia. Where leaking blood vessels and blood pressure changes can create dementia. Where circulation and heart health can change ability to remember and retain information. I only recently started seeing information on how septic infections can distort thinking.

But if we don't talk about how we think or see something normally, how do we know it is distorted thinking for that person?

There are physical factors. There are mental factors. There are genetic factors. There are environmental factors.

Please normalize neurodivergence, for everyone's sake.

Please talk about neurodivergence more.

[covid-safer-hotties]

Viral pathogens increase risk of neurodegenerative disease - Published Mar 2, 2023

Neurodegenerative diseases, which include conditions such as Alzheimer disease (AD) Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), vascular dementia and multiple sclerosis (MS), are a class of progressive disorders defined by neuronal death. Each of these disorders is characterized by degeneration of distinct brain areas, and they present with overlapping but discrete symptoms that can include motor impairment, cognitive dysfunction, affective changes and/or dementia. With the exception of rare familial cases, the aetiopathogenic origins of these diseases are poorly understood; however, two common factors seem to be neuroinflammation and epidemiological links to viral infections.

Neuroinflammation was originally thought to be a consequence of neurodegeneration; however, subsequent research indicated that neuroinflammation can drive the onset and progression of neurodegenerative diseases. The idea of neuroinflammation as a driver of neurodegeneration was advanced by genome-wide association studies (GWAS) that identified immune-related genes, including CD33 and TREM2, as risk factors for AD2. In addition, the ε4 allele of the apolipoprotein E gene (APOE ε4), which is the strongest known genetic risk factor for AD and accounts for approximately 10–20% of the risk of late-onset disease, has been hypothesized to exert its effects partially through neuroinflammatory processes. These genetic factors increase the risk of developing neurodegenerative disease but are not sufficient to cause disease on their own. Instead, genetic risk factors are likely to work with environmental factors that underlie sporadic forms of neurodegenerative disease.

Read the full article and find even more covid news, science, and advice at our archive:

[cbirt]

AI-Powered Dementia Detection: A Digital Solution for Identifying Undiagnosed Cases

Scientists from the Regenstrief Institute, IUPUI, Indiana University, and the University of Miami are using Artificial Intelligence to identify undiagnosed cases of dementia in primary care settings as part of the Digital Detection of Dementia (D3) study. The study aimed to improve the timely diagnosis of dementia and provide diagnostic services to those who have been identified as cognitively impaired.

Alzheimer’s disease and other forms of dementia (ADRD) impact millions of Americans and their caregivers, with an annual societal cost of over $200 million. Unfortunately, many people with ADRD go undiagnosed, and even when a diagnosis is made, it often comes 2 to 5 years after the onset of symptoms, when the disease is already in the mild to moderate stage. This delay in diagnosis reduces the chances of improving outcomes through drug and non-drug treatments and prolongs the expense of medical care. Also, delayed detection results in increased disabilities for patients, families, and society, and traditional methods such as cognitive screening tests and biological markers often fail to detect ADRD in primary care.

The researchers developed an AI tool called a Passive Digital Marker, which uses a machine learning algorithm and natural language processing to analyze a patient’s electronic health record. The tool combines structured data, such as notes about memory problems or vascular issues, with unstructured information to identify potential indicators of dementia.

Continue Reading

[albonium]

the lab tech told me there's a huge covid wave right now (how surprising lol)

it's always the right time to start masking with a well fitting ffp2 or n95 mask, for your health and the health of your family friends and community including people with disabilities and health problems

first of all covid is airborne it means it behaves in the air like a deodorant or an airwick spray. staying at a distance from someone will only spare you some of the droplets but not the whole thing.

covid often causes lots of different issues in the human body, even when it's an asymptomatic infection, regardless of age and health: cardio vascular system, lungs, nervous system/brain/early dementia/memory/depression, immune system, taste smell vision and hearing loss. there's is about 20% chance of getting long covid each time you get infected and risk increase with the number of infections even if they're asymptomatic. long covid can take different forms but basically people are disabled with lots of conditions making making their life quality shit. some are bed bound with symptoms similar to pots or neurological diseases.

the vaccine only prevents severe reactions to the infection and only works for some variants. if you haven't gotten a booster in the last 6 months/year it's not effective anymore

the main tools we have are well fitting ffp2/ffp3/n95 masks, air ventilation/purifying and testing

[ausetkmt]

New Alzheimer's drugs bring hope. But not equally for all patients.

https://www.washingtonpost.com/health/2024/01/29/alzheimers-new-drugs-black-patients-leqembi/

ABINGTON, Pa. — Wrapped in a purple blanket, Robert Williford settles into a quiet corner of a bustling neurology clinic, an IV line delivering a colorless liquid into his left arm.

The 67-year-old, who has early Alzheimer’s disease, is getting his initial dose of Leqembi. The drug is the first to clearly slow the fatal neurodegenerative ailment that afflicts 6.7 million older Americans, though the benefits may be modest. The retired social worker, one of the first African Americans to receive the treatment, hopes it will ease his forgetfulness so “I drive my wife less crazy.”

But as Williford and his doctors embark on this treatment, they are doing so with scant scientific data about how the medication might work in people of color. In the pivotal clinical trial for the drug, Black patients globallyaccounted for only 47 of the 1,795 participants — about 2.6 percent. For U.S. trial sites, the percentage was 4.5 percent.

The proportion of Black enrollees was similarly low for Eli Lilly Alzheimer’sdrug, called donanemab, expected to be cleared by the Food and Drug Administration in coming months. Black people make up more than 13 percent of the U.S. population.

The paltry data for the new class of groundbreaking drugs, which strip a sticky substance called amyloid beta from the brain, has ignited an intense debate among researchers and clinicians. Will the medications — the first glimmer of hope after years of failure — be as beneficial for African Americans as for White patients?

“Are these drugs going to work in non-Whites? And particularly in Blacks? We just don’t have enough data, I don’t think,” said Suzanne E. Schindler, a clinical neurologist and dementia specialist at Washington University in St. Louis. “In general, the default is that they will work the same in everybody, but we don’t really know that for sure.”

The situation casts a spotlight yet again on the decades-long failure of researchers to reflect the increasingly diverse character of the patient population in the United States, and underscores the stark disparities in Alzheimer’s treatment and care. Black Americans develop the disease and related dementias at twice the rate of their White counterparts, but are less likely to receive specialized care and are diagnosed at later stages, studies show. That’s an urgent problem considering that the new drugs must be used early to have an effect.

In addition, a perplexing new issue appears to be contributing to low Black enrollment in trials and is fueling a debate among experts about the role of race, genetics and other factors. To qualify for the main trial for Leqembi — developed by the Japanese pharmaceutical giant Eisai and the biotechnology company Biogen of Cambridge, Mass. — participants were required to have elevated levels of brain amyloid, a defining characteristic of Alzheimer’s, and symptoms such as memory loss.

But brain scans showed that the African American volunteers were less likely to have excess amyloid than White patients and thus were excluded from the trial at higher rates. Almost half of Black applicants failed to meet the amyloid threshold, compared with 22 percent of White volunteers, according to Eisai. A similar pattern occurred with the Lilly drug and in some other studies, and sometimes involved other people of color, including Hispanics.

Experts are baffled by the findings. Why would amyloid levels — thought to be a key driver of Alzheimer’s — be different in people with similar cognitive problems?

“Is it the color of someone’s skin? Almost certainly not,” said Joshua D. Grill, an Alzheimer’s researcher at the University of California at Irvine. “Is it a difference in genetics? Or other health conditions, like cholesterol, blood pressure or vascular health? Or is it something else, that we haven’t measured?”

While the biology of Alzheimer’s is almost surely the same regardless of race, some researchers say the patients themselves might be different because of underlying health conditions. Some older Black patients diagnosed with Alzheimer’s, they say, might actually have vascular dementia stemming from heart disease, hypertension and diabetes — all conditions more prevalent among African American patients.

The risk of vascular damage also could be increased by a lack of access to health care and years of exposure to racism, as well as genetics, some experts say. And many patients could have a constellation of pathologies driven by other factors, they add.

Whatever the cause, experts say, the bottom line is the same: Patients who do not have excessive amounts of the sticky brain protein should not be treated with the amyloid-targeting drugs because the therapies are unlikely to work and pose substantial risks, including potentially deadly bleeding in the brain.

But that raises the specter of another disparity. If it turns out that a lower proportion of Black dementia patients and other people of color have excess amyloid, they could be left behind as the drug industry races to develop amyloid-reducing treatments. To counter that, experts are urging companies to accelerate work addressingother potential drivers of cognitive decline and to develop combination drugs with multiple targets.

“If we are just targeting amyloid, we can just miss a large potential population that might benefit from treatment,” said Lisa L. Barnes, a neuropsychologist at Rush University in Chicago.

‘A brain is a brain’

For now, the question remains: What should Black patients and their doctors think about the anti-amyloid drugs?

The answer, experts say, depends largely on the level of amyloid in their brains.

More than a year ago, Williford was diagnosed with early Alzheimer’s by David C. Weisman, a neurologist at Abington Neurological Associates, a large practice north of Philadelphia that treats patients and conducts clinical trials for drug companies. The clinic was one of the test sites for Leqembi.

After Leqembi receivedfull FDA approval last summer, Williford underwent tests to determine whether he was a good candidate for the drug. One test — a lumbar puncture, sometimes called a spinal tap — showed elevated amyloid in his brain. That means Williford and similar patients are likely to benefit from an anti-amyloid medication regardless of their race or ethnicity, Weisman and several other experts said.

“A brain is a brain is a brain, whether it is Asian, Hispanic, African American or White,” Weisman said. “A patient is either a good fit or a bad fit, and Robert is a good fit.”

Williford, who spent years working with troubled families in Philadelphia, began having memory problems a few years ago, said his wife, Cynthia Byron-Williford, 59.

“You could tell him almost anything, and he would almost immediately forget,” she said. “If I asked him to make a peanut butter sandwich for our grandson, he would come back three times and say, ‘What am I supposed to do?’”

With few treatment options, many physicians say they will offer anti-amyloid therapy to any patient who has elevated levels of the substance and passes safety tests.

Barry W. Rovner, a neurology professor at Thomas Jefferson University in Philadelphia, said he would not hesitate to offer Leqembi to African American patients who tested positive for amyloid. But, he added, because of the low numbers of Black individuals in the Leqembi trial, “I would say, ‘Look, this has not been tried in many Black people, so we don’t know precisely how it is going to work. But you don’t know precisely how it will work in any person.’”

From a research perspective, “You could say, as a group we don’t know if Black individuals respond the same way to anti-amyloid drugs because we don’t have the data,” Washington University’s Schindler said. “But on an individual level, it is different. If I had a Black patient who was amyloid-positive, I would start him on these drugs.”

But some Black patients might not be comfortable with the medication.

Zaldy S. Tan, director of the memory disorders center at Cedars-Sinai Medical Center in Los Angeles, said when African American patients are informed about the risks and benefits of Leqembi, and about the sparse data available for Black individuals, some will “take a pause and question whether they are willing to accept the uncertainty” and challenges of receiving the every-other-week infusion and multiple follow-up tests.

A promise of diversity

The best way to know for sure how drugs for Alzheimer’s — and other diseases — affect different populations is to have more diversity in trials, experts agree. But research participation by Black Americans and other people of color has been held down for years for several reasons.

The 20th century’s infamous Tuskegee syphilis study created long-standing mistrust about trials within the African American community. Men were left untreated to suffer and die even after an effective treatment emerged for the bacterium.

Alzheimer’s research, meanwhile, has long been centered in memory clinics at elite academic institutions, which tend to attract well-heeled patients with health insurance and other resources. The clinics have served as effective recruiting grounds for trials that end up with a predominantly White enrollment.

“We have done a poor job of making African American Alzheimer’s research inclusive,” said John Morris, a neurologist at Washington University in St. Louis. More than two decades ago, he created an African American advisory board at the school’s Knight Alzheimer Disease Research Center after realizing only 3 percent of trial participants were Black.

Others also are redoubling efforts to increase diversity. John Dwyer, president of the Global Alzheimer’s Platform Foundation, a nonprofit that runs trials, said the organization has sharply increased participation by people of color by sending dedicated teams of African American and Latino professionals into communities to build relationships with physicians and personnel at health centers, senior centers and places of worship. They stress to the communities how much they can benefit from the studies, he said.

Stephanie Monroe, vice president and senior adviser of health equity and access at the advocacy group UsAgainstAlzheimer’s, noted that low Black enrollment is not limited to Alzheimer’s trials. If all the drugs that have not been tested on people of color were eliminated, the shelves of pharmacies would be nearly empty, she said.

“That doesn’t work when you are almost a 50-50 minority/majority population,” Monroe said.

The FDA has issued guidelines for industry designed to bolster diversity in studies, while the National Institute on Aging recently pledged toprioritize funding requests that are “appropriately inclusive.”

The low Black enrollment in studies is just the latest controversy involving the anti-amyloid drugs. For years, earlier versions of the drugs failed repeatedly in trials. By contrast, Leqembi, in an 18-month trial, showed unambiguous, if modest, benefits, slowing disease progression by about 27 percent, or roughlyfive months. The drug, administered every other week, carries a list price of $26,500 a year.

In July, Lilly reported that its anti-amyloid drug, donanemab, was even more effective at removing amyloid. But like Leqembi, it can cause serious side effects, including brain hemorrhages. Some doctors think the drugs will provide bigger benefits when taken for a longer period or earlier in the disease, but others say the medications, which require repeated MRIs to check for side effects, leave much to be desired.

Both Eisai and Lilly said they are working hard to increase diversity in clinical trials. In the meantime, they said, patients with elevated amyloid should benefit from the anti-amyloid drugs, regardless of race or ethnicity.

“We have no pathophysiological reason to expect different efficacy between races and ethnicities for Alzheimer’s treatments that remove amyloid,”Lillysaid in a statement.

Eisai acknowledged that the Leqembi trial was not designed to test the drug in individual racial and ethnic subgroups. But it said in a statement that the totality of the evidence indicated that “all patients, regardless of ethnicity, benefited from treatment” with the drug.

“We and the U.S. FDA — as evidenced by the agency’s approval of Leqembi — believe that the benefits and risks in these patient populations and races has been established,” the company added. Eisai said volunteers who did not pass the amyloid threshold did not have Alzheimer’s and should be assessed for other conditions.

In an interview, Teresa Buracchio, acting director of the FDA’s Office of Neuroscience, said the agency “did not see a notable difference by race” in safety and effectiveness in the limited data available on subgroups in the Leqembi trial.

But other experts were skeptical, saying the number of Black patients in the Leqembi trial was too low to know whether the medication is safe and effective for African Americans. “Without having a representative population, it is impossible to assess,” said Barnes, of Rush University.Some researchers suggested that patients in underrepresented populations should wait for future advances in treatment.

‘We just want to get going’

On a recent day, nurse Christine Besso bustled in and out of Williford’s infusion room at the neurology clinic, taking his vital signs and inserting an IV line. “Let’s get this party started,” she said.

Byron-Williford, watching the process from a nearby couch, said she was not concerned about the low numbers of African Americans in the Leqembi trial.

“I think it will work or not work based on the individual,” she said, adding with a laugh, “and if it doesn’t work for him, it is because he is ornery.”

Byron-Williford said her husband’s health problems accelerated a few years ago after his son, who was in his early 20s, died unexpectedly. Williford became depressed and lost his appetite. Last summer, when he went to pick up his wife at a nearby hair salon, he drove around, lost. She later confiscated his car keys.

In the clinic, shortly after Williford’s infusion began, Weisman stopped in to check on him and discuss possible side effects. When Williford asked him how long he would be on the drug, Weisman shrugged, saying it depended on how he did on the drug and on test results.

“We are getting on an airplane, and we don’t even have a destination airport yet,” Weisman said. “We just want to get going.”

[pandemic-info]

Saving another one; not mine:

All of the studies coming out - ALL of them - show repeated Covid infections being really bad for you. For your brain. For your vascular system. For your immune system. I think if we wait 5 to 10 years it will become super obvious. If you watch local groups sometimes it already is - the mom who’s kid is on week 4 of strep despite multiple rounds of antibiotics, the man with the lingering cough he just can’t seem to shake, the gofundme for the dad in his 30s who died of a stroke, the lady who is just so tired recently and just can’t shake it, the people in their 40s complaining about memory loss and how they are getting old. The thing is humanity has plenty of experience with diseases that aren’t too bad at first and are REALLY bad later on - HIV is a mild cold on first infection, mono sucks but goes away to become MS later, chicken pox is a one week wonder but shingles can cause permanent complications. Heck anyone who has played Plague Inc knows the best way to infect everyone is to make your virus have extremely mild or no initial symptoms so that people don’t worry about it and then ramp up the consequences once everyone is infected. And now that people have allowed themselves and their children to get infected because they needed youth sports and going out to eat and 50,000 person concerts without masks, if they acknowledge that that was a bad choice, then what? They have to admit they were wrong and that they might face a lifetime of consequences because of it. That they may have shortened their own lives and their children’s lives. And if there is anything modern people are not prepared to do, it is admit they were wrong. Or to do anything that goes counter to their own personal comfort. Ultimately if I am wrong, and Covid is no big deal, in 5 years I can take off my mask. In the meantime, I didn’t catch every cold, every flu and every case of strep throat going around. But I can take my mask off at any time and blend right back in. If I’m right about the dangers of Covid, I can’t go maskless now and decide to mask in 5 years and have my body be ok. If I make the choice to unmask now, I lose my choices to live a meaningful life later. I’ve seen early onset dementia, people who are immunocompromised and have to live limited lives to stay alive, people with various illnesses who can’t do so many things. I would much rather choose to limit myself from giant concerts and indoor dining than have my body limit me from walks and playing with my kids and grocery stores. My life is full and meaningful now. Different than before and I’ve lost most of my social relationships. But I am slowly building new ones with other people who still Covid locally and I spend time with my immediate family. It is hard and it feels a bit nuts sometimes. And then I go on Twitter and read the latest published study in Science and go, yep don’t want that.

[leebird-simmer]

Psychopathology, Ch. 14

Describe the diagnostic features of neurocognitive disorders and identify three major types.

A neurocognitive disorder involves a significant disturbance or deficit of thinking or memory that represents a marked decline in cognitive functioning. They are caused by physical or medical conditions or drug use or withdrawal affecting the functioning of the brain. The three major types identified in DSM-5 are delirium, major neurocognitive disorder, and mild neurocognitive disorder.

Agnosia: a disturbance of sensory perception, usually affecting visual perception.

Describe the key features and causes of delirium.

Delirium: characterized by symptoms such as impaired attention, disorientation, disorganized thinking and rambling speech, reduced level of consciousness, and perceptual disturbances. Delirium is most commonly caused by alcohol withdrawal, as in the form of DTs, but may also occur in hospitalized patients, especially after major surgery.

Describe the key features and causes of major neurocognitive disorder.

Major neurocognitive disorder: a significant cognitive deterioriation or impairment, as evidenced by memory deficits, impaired judgment, personality changes, and disorders of high cognitive functions such as problem-solving ability and abstract thinking. Dementia is not a normal consequence of aging; rather, it is a sign of a degenerative brain disorder. There are various causes of major neurocognitive disorder, including Alzheimer’s disease and Pick’s disease, and brain infections and disorders.

General paresis: a form of dementia resulting from neurosyphilis.

Late-onset dementia: forms of dementia that begin after age 65.

Early-onset dementia: forms of dementia that begin before age 65.

Describe the key features of mild neurocognitive disorder.

Mild neurocognitive disorder: a milder decline in cognitive functioning. The person with the disorder is able to function but needs to expend greater effort or use compensatory strategies to compensate for cognitive declines.

Describe the key features and causes of Alzheimer’s disease and evaluate current treatments.

Alzheimer’s disease (AD): a progressive brain disease characterized by progressive loss of memory and cognitive ability, as well as deterioration in personality functioning and self-care skills. There is neither a cure nor an effective treatment for AD. Currently available drug treatments offer only modest effects at best. Research into the causes of the disease points to roles for genetic factors and factors involved in the accumulation of amyloid plaques in the brain.

Identify other subtypes of neurocognitive disorders.

Other medical conditions can lead to neurocognitive disorders, including vascular disease, Pick’s disease, Parkinson’s disease, Huntington’s disease, prion disease, HIV infection, and head trauma.

Cerebrovascular accident (CVA): a stroke or brain damage resulting from a rupture or blockage of a blood vessel supplying oxygen to the brain.

Vascular neurocognitive disorder: dementia resulting from repeated strokes that cause damage in the brain.

Aphasia: impaired ability to understand or express speech.

Pick’s disease: a form of dementia, similar to Alzheimer’s disease, but distinguished by specific abnormalities (Pick’s bodies) in nerve celles and the absence of neurofibrillary tangles and plaques.

Amnesia: memory loss that frequently follows a traumatic event such as a blow to the head, an electric shock, or a major surgical operation.

Retrograde amnesia: loss or impairment of ability to recall past events.

Anterograde amnesia: loss or impairment of ability to form or store new memories.

Hypoxia: decreased supply of oxygen to the brain or other organs.

Infarction: the development of an infarct (an area of dead or dying tissue) resulting from the blocking of blood vessels that normally supply the tissue.

Korsakoff’s syndrome: a syndrome associated with chronic alcoholism that is characterized by memory loss and disorientation.

Wernicke’s disease: a brain disorder, associated with chronic alcoholism, characterized by confusion, disorientation, and difficulty maintaining balance while walking.

Ataxia: loss of muscle coordination.

Lewy bodies: abnormal protein deposits in brain cells that cause a form of dementia.

Parkinson’s disease: a progressive disease characterized by muscle tremors and shakiness, rigidity, difficulty walking, poor control of fine motor movements, lack of facial muscle tone, and (in some cases) cognitive impairment.

Huntington’s disease: an inherited degenerative disease that is characterized by jerking and twisting movements, paranoia, and mental deterioration.

Identify anxiety-related disorders and their treatments in older adults.

Generalized anxiety disorder and phobic disorders are the most common anxiety disorders among older people. Problems with anxiety are often treated with anti-anxiety medical or psychological treatment such as cognitive behavioral therapy.

Identify factors associated with depression in late adulthood and ways of treating it.

Factors include the challenge of coping with life changes, such as retirement, physical illness or incapacitation, placement in a residential facility or nursing home; lack of social support as the result of death of a spouse, siblings, lifetime friends, and acquaintances; and need to care for a spouse whose health is declining. Among immigrant groups and people of color, factors such as acculturative stress and coping with racism also play a role. Available treatments for depression in older as well as younger adults include anti-depressant medication, cognitive behavioral therapy, and interpersonal psychotherapy.

Identify factors involved in late-life insomnia and ways of treating it.

Sleep problems, especially insomnia, are common among older adults – more common in fact than depression. Insomnia is often linked to other psychological disorders, medical illness, psychosocial factors such as loneliness and sleeping alone after losing a spouse, and dysfunctional thoughts. Behavioral techniques are effective for treating insomnia in older as well as younger adults.

[myhealthnote]

High blood pressure

High blood pressure, or hypertension, is a major health problem that is common in older adults. Your body’s network of blood vessels, known as the vascular system, changes with age. Arteries get stiffer, causing blood pressure to go up. This can be true even for people who have heart-healthy habits and feel just fine. High blood pressure, sometimes called "the silent killer," often doesn't cause signs of illness that you can see or feel. Though high blood pressure affects nearly half of all adults, many may not even be aware they have it.

If high blood pressure isn't controlled with lifestyle changes and medication, it can lead to serious health problems, including cardiovascular disease (such as heart disease and stroke), vascular dementia, eye problems, and kidney disease. The good news is that blood pressure can be controlled in most people.

What is blood pressure?

Blood pressure is the force of blood pushing against the walls of arteries as the heart pumps blood. When a health care professional measures your blood pressure, they use a blood pressure cuff around your arm that tightens and then gradually loosens. The results are given in two numbers. The first number, called systolic blood pressure, is the pressure caused by your heart contracting and pushing out blood. The second number, called diastolic blood pressure, is the pressure when your heart relaxes and fills with blood.

A blood pressure reading is given as the systolic blood pressure number over the diastolic blood pressure number. Blood pressure levels are classified based on those two numbers.

Low blood pressure, or hypotension, is systolic blood pressure lower than 90 or diastolic blood pressure lower than 60. If you have low blood pressure, you may feel lightheaded, weak, dizzy, or even faint. It can be caused by not getting enough fluids, blood loss, some medical conditions, or medications, including those prescribed for high blood pressure.

Normal blood pressure for most adults is defined as a systolic pressure of less than 120 and a diastolic pressure of less than 80.

Elevated blood pressure is defined as a systolic pressure between 120 and 129 with a diastolic pressure of less than 80.

High blood pressure is defined as systolic pressure of 130 or higher, or a diastolic pressure of 80 or higher.

For older adults, often the first number (systolic) is 130 or higher, but the second number (diastolic) is less than 80. This problem is called isolated systolic hypertension and is due to age-related stiffening of the major arteries. It is the most common form of high blood pressure in older adults and can lead to serious health problems in addition to shortness of breath during light physical activity, lightheadedness upon standing too fast, and falls.

One reason to visit your doctor regularly is to have your blood pressure checked and, if needed, plan how to manage your blood pressure.

Do I have high blood pressure?

Anyone can have high blood pressure. Some medical conditions, such as metabolic syndrome, kidney disease, and thyroid problems, can cause high blood pressure. Some people have a greater chance of having it because of things they can't change. These include:

Age. The chance of having high blood pressure increases as you get older, especially isolated systolic hypertension.

Gender. Before age 55, men have a greater chance of having high blood pressure. Women are more likely to have high blood pressure after menopause.

Family history. High blood pressure runs in some families.

Race. African Americans are at increased risk for high blood pressure.

High blood pressure often has no signs or symptoms, but routine checks of your blood pressure will help detect increasing levels. If your blood pressure reading is high at two or more check-ups, the doctor may also ask you to measure your blood pressure at home.

There are important considerations for older adults in deciding whether to start treatment for high blood pressure, including other health conditions and overall fitness. Your doctor will work with you to find a blood pressure target that is best for your well-being and may suggest exercise, changes in your diet, and medications.

How can I control my blood pressure?

You can often lower your blood pressure by changing your day-to-day habits and by taking medication if needed. Treatment requires ongoing evaluation and discussions with your doctor, especially if you have other medical conditions such as diabetes.

Lifestyle changes you can make to help prevent and lower high blood pressure:

Aim for a healthy weight. Being overweight adds to your risk of high blood pressure. Ask your doctor if you need to lose weight. In general, to maintain a healthy weight, you need to burn the same number of calories as you eat and drink.

Exercise. Moderate activity, such as brisk walking or swimming, can lower high blood pressure. Set goals so you can exercise safely and work your way up to at least 150 minutes (2.5 hours) per week. Check with your doctor before starting an exercise plan if you have any health problems that aren't being treated.

Eat a heart-healthy diet. A balanced diet of vegetables, fruits, grains, protein, dairy, and oils — such as the Dietary Approaches to Stop Hypertension (DASH) eating plan — can lower your blood pressure.

Cut down on salt. As you get older, the body and blood pressure become more sensitive to salt (sodium), which is added to many foods during processing or preparation. Limiting your amount of salt each day may help. DASH is a low-salt diet.

Drink less alcohol. Drinking alcohol can affect your blood pressure. For those who drink, men should have no more than two drinks a day and women no more than one a day to lower their risk of high blood pressure.

Don't smoke. Smoking increases your risk for high blood pressure, heart disease, stroke, and other health problems. If you smoke, quit. The health benefits of quitting can be seen at any age — you are never too old to quit.

Get a good night's sleep. Tell your doctor if you've been told you snore or sound like you stop breathing for moments when you sleep. This may be a sign of a problem called sleep apnea. Treating sleep apnea and getting a good night's sleep can help to lower blood pressure.

Manage stress. Coping with problems and reducing stress can help lower high blood pressure.

In addition to recommending lifestyle changes, your doctor will likely prescribe medication to lower your blood pressure to a safe level. Isolated systolic hypertension, the most common form of high blood pressure in older adults, is treated in the same way as regular high blood pressure but may require more than one type of blood pressure medication. You may try several kinds or combinations of medications before finding a plan that works best for you. Medication can control your blood pressure, but it can't cure it. If your doctor starts you on medication for high blood pressure, you may need to take it long term.

Research shows the benefits of controlling high blood pressure

Preventing and controlling high blood pressure is important for your heart health and may benefit your brain health as well. An NIH-funded study called the Systolic Blood Pressure Intervention Trial (SPRINT) found that lowering systolic blood pressure to less than 120 in adults age 50 and older significantly reduced the risk of cardiovascular disease and death. Results from a related study showed that lowering systolic blood pressure to less than 120 reduced the risk of mild cognitive impairment, and an analysis of several large, long-term studies of adults over age 55 found that treating high blood pressure was associated with a reduction in the risk of developing Alzheimer’s disease.

Tips for taking blood pressure medication

Untreated high blood pressure can increase your risk of serious health problems. If your doctor prescribes medication to lower your blood pressure, remember:

If you take blood pressure medication and your blood pressure goes down, it means medication and lifestyle changes are working. If another doctor asks if you have high blood pressure, the answer is, "Yes, but it is being treated."

Healthy lifestyle changes may help lower the dosage you need.

Get up slowly from a seated or lying position and stand for a bit before walking. This lets your blood pressure adjust before walking to prevent lightheadedness and falls.

Tell your doctor about all the drugs you take. Don't forget to mention over-the-counter drugs, as well as vitamins and supplements. They may affect your blood pressure. They also can change how well your blood pressure medication works.

Blood pressure medication should be taken at the same time each day as part of your daily routine. For example, take it in the morning with breakfast or in the evening before brushing your teeth. Talk to the pharmacist if you have any questions about when or how to take your medication.

Remember to refill your medication before you run out and bring it with you when traveling. It’s important to keep taking your medication unless your doctor tells you to stop.

Before having surgery, ask your doctor if you should take your blood pressure medication on the day of your operation.

VITAPOST BLOOD PRESSURE SUPPORT

VitaPost Blood Pressure Support is formulated to support blood pressure levels already within the normal range. This dietary supplement can nutritionally support heart health, cardiovascular health, and a healthy lifestyle. get yours now https://htm101.com/track.php?c=cmlkPTgyMjU3NyZhaWQ9NDU1NTc1NT

The exotic featured ingredients, Hibiscus, Olive Leaf and Hawthorn, are all attractive and bring evidenced blood pressure support, antioxidant properties and a history of traditional use. In the health media you can find relatively strong blood pressure claims about them, especially Hibiscus and Olive Leaf. For those customers that are looking for garlic, vitamin B12, folate, and vitamin B6, all these ingredients are well represented too.

One bottle contains 90 capsules, which is equivalent to a 1-month supply at max usage, or can last as long as 3 months at the minimum usage.

Benefits of Blood Pressure Support:

Supports cardiovascular health;

Supports a healthy heart and circulatory system;

Supports healthy blood pressure within the normal range.

Blood Pressure Support is made in the US in an FDA registered facility that follows GMP guidelines. Ingredients in the formula are both domestic and imported.

This solid and respectable offer represents a great opportunity to profit from the blood pressure supplements market.

place your order now https://htm101.com/track.php?c=cmlkPTgyMjU3NyZhaWQ9NDU1NTc1NT

[katherinemathew]

Dementia Action Week: Understanding and Supporting

Dementia Action Week, from 16–22 September, encourages everyone to increase their understanding of dementia and explore ways to create more inclusive, supportive communities for people living with the condition.

What is Dementia?

Dementia is a condition that affects the brain, causing memory loss, difficulty with thinking, and changes in behaviour and emotions. It’s not a natural part of ageing and can affect people of all ages, but most commonly affects people over the age of 65.

The most common type is Alzheimer’s disease, but there are other types, such as vascular dementia and Lewy body dementia.

Are Alzheimer’s Disease and Dementia Different, or are they the same thing?

‘Alzheimer’s disease’ is the most common and well-known type of dementia.

‘Dementia’ is a general ‘umbrella’ term for a decline in cognitive ability that interferes with daily life, while Alzheimer’s disease is a specific brain disease that causes a gradual decline in memory and thinking skills, and falls under the umbrella term of ‘dementia’.

Early Warning Signs for Dementia

Recognising the early signs of dementia is important for early diagnosis and management for you or your loved one.

Some common early warning signs include:

Difficulty completing everyday tasks, like preparing meals or paying bills.

Disorientation, including confusion about time or location.

Language difficulty, such as forgetting words or using the wrong ones.

Personality and mood changes, including sudden mood swings or withdrawal.

Frequently misplacing regularly used items such as keys, or putting them in odd places.

If you notice these signs in yourself or a loved one, it’s a good idea to speak with a healthcare professional, such as your GP, for further advice.

Symptoms of Dementia

Dementia affects people in many different ways and not everyone experiences symptoms the same way. Some common symptoms include:

Short-term memory loss, such as forgetting recent conversations or events.

Difficulty with problem-solving or making everyday decisions.

Challenges with communication and understanding language.

Confusion about time and place, including difficulty navigating familiar environments.

Changes in behaviour, such as becoming restless or agitated.

Decline in mobility, and fine motor skills.

Despite these symptoms, many people living with dementia can still maintain meaningful connections and enjoy fulfilling activities with the right care and understanding.

How to Support a Loved One Living with Dementia

Supporting someone living with dementia can make a huge difference to their wellbeing.

Here are five key tips:

Be patient and reassuring: Offer calm, supportive responses to help ease anxiety and frustration. Never argue with them, but meet them where they are in their mind.

Stay connected: Regular interaction helps your loved one feel connected and supported.

Maintain a safe, familiar environment: Familiar surroundings and routines can help reduce confusion.

Encourage independence: Let them do what they can on their own to boost confidence and self-esteem.

Keep learning: Understanding more about dementia will help you better support your loved one and prepare for the future.

Read the full article to know more about Dementia Action Week: Understanding and Supporting

#mayflower #inhomeagedcare #homecarepackages #homecarepackagesproviders

[sokittybanana]

Alzheimer’s & Dementia Care | Vero Beach, FL | Aqua Home Care

Navigating the journey of dementia can be challenging for both individuals and their families. In Vero Beach, FL, specialized dementia care services are available to provide essential support, guidance, and compassion for those affected by this condition. Understanding Dementia Vero Beach FL and its impact is the first step toward ensuring that your loved ones receive the quality care they need.

Understanding Dementia

Dementia is not a specific disease but a general term that encompasses various cognitive impairments that affect memory, thinking, and social abilities. Common types include Alzheimer’s disease, vascular dementia, and Lewy body dementia. Symptoms can vary widely but often include memory loss, confusion, difficulty communicating, and changes in mood or behavior.

Importance of Specialized Care in Vero Beach

Tailored Care Plans: Dementia Vero Beach FL focuses on creating personalized care plans that address the unique needs of each individual. Caregivers work closely with families to ensure that all aspects of the person's well-being—physical, emotional, and social—are supported.

Trained Professionals: Caregivers specializing in dementia are trained to understand the complexities of the condition. They are equipped with strategies to manage challenging behaviors, provide effective communication techniques, and ensure safety in daily activities.

Engagement and Activities: Keeping individuals with dementia engaged is crucial for their mental and emotional health. Programs in Vero Beach often include memory-boosting activities, art therapy, and social engagement opportunities tailored to different cognitive levels.

Family Support: Caring for someone with Dementia Vero Beach FL can be overwhelming for families. Many local services in Vero Beach offer resources, support groups, and educational programs to help families understand the disease and navigate their caregiving roles.

Respite Care Options: For family caregivers, taking a break is essential for maintaining their own health and well-being. Respite care services in Vero Beach provide temporary relief, allowing family members to recharge while ensuring their loved ones are in safe hands.

Community Resources in Vero Beach

Vero Beach is home to various resources that cater to the needs of those living with dementia. Local support groups, educational workshops, and community events provide valuable information and connections for families. Healthcare providers in the area also specialize in geriatric care, ensuring comprehensive medical support for dementia patients.

Conclusion

In Vero Beach, FL, families grappling with dementia can find compassionate and specialized care tailored to their loved ones' needs. By choosing dedicated Dementia Vero Beach FL services, families can ensure their loved ones receive the support and engagement necessary for a better quality of life. If you’re looking for dementia care options in Vero Beach, explore the local services available and take the first step toward providing your loved ones with the compassionate care they deserve. Together, we can navigate this journey with understanding, patience, and love.

[openintegrative]

Dementia: Causes, Symptoms, and Management

Dementia involves a decline in cognitive function affecting memory, thinking, and daily life.

Common causes include genetic factors, aging, and certain medical conditions.

Early symptoms often involve memory loss, mood changes, and difficulty with communication.

Management includes medication, lifestyle adjustments, and caregiver support.

Preventive measures focus on healthy living and managing chronic diseases.

Introduction to Dementia

Dementia refers to a group of conditions marked by a decline in cognitive abilities severe enough to interfere with daily activities.

Alzheimer’s disease is the most common type, but other forms include vascular dementia, Lewy body dementia, and frontotemporal dementia.

Causes and Risk Factors

Dementia can arise from several causes, with age being the most significant factor. Genetics also contribute, particularly in early-onset cases.

Medical conditions like hypertension, diabetes, and cardiovascular disease increase the risk, as do lifestyle factors such as smoking, poor diet, and lack of exercise.

Symptoms and Early Signs

Dementia symptoms vary, but common early signs include memory loss, especially of recent events.

Individuals may experience confusion, have trouble with language, and struggle with problem-solving. Mood changes, including depression, anxiety, and irritability, often accompany cognitive decline.

These symptoms progressively impair the ability to perform everyday tasks.

Diagnosis of Dementia

Diagnosing dementia requires a comprehensive medical evaluation. Doctors typically conduct cognitive tests to assess memory, language, and problem-solving abilities.

Brain imaging, such as MRI or CT scans, helps detect changes in brain structure. Blood tests and other assessments are used to rule out other possible causes of symptoms.

Treatment and Management

While there is no cure for dementia, treatments aim to manage symptoms and improve quality of life.

Lifestyle changes, including a balanced diet and regular physical activity, support overall brain health. When done properly, the ketogenic diet in particular can provide significant benefits on multiple fronts.

Caregiver support is essential, providing emotional and practical assistance to those affected.

Medications like cholinesterase inhibitors and memantine can help manage cognitive symptoms.

Coping with Dementia

Living with dementia requires adapting to new challenges. Establishing routines and using memory aids can help maintain independence.

Strong support networks, including family, friends, and professional caregivers, are vital. Legal and financial planning ensures future needs are met.

Prevention and Risk Reduction

Preventing dementia involves adopting healthy lifestyle habits.

Regular exercise, a diet rich in nutrients, and mental stimulation are key strategies.

Social engagement also supports cognitive health. Managing chronic conditions like hypertension and diabetes can reduce the risk of developing dementia.

FAQ

What is dementia? Dementia is a condition marked by a decline in cognitive function, affecting memory, thinking, and daily activities.

What causes dementia? Dementia can be caused by genetic factors, aging, medical conditions like hypertension and diabetes, and lifestyle choices.

How is dementia diagnosed? Diagnosis involves cognitive tests, brain imaging, and medical evaluations to assess symptoms and rule out other conditions.

Can dementia be treated? While dementia cannot be cured, treatments focus on managing symptoms, improving quality of life, and providing caregiver support.

What can be done to prevent dementia? Prevention involves maintaining a healthy lifestyle, including regular exercise, a nutrient-rich diet, and mental and social engagement.Research

Abbasi, U., Abbina, S., Gill, A., Takuechi, L.E., & Kizhakkedathu, J.N. (2021). Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities. ACS Chemical Biology, 16(6), 945–972. https://doi.org/10.1021/acschembio.1c00122

Atkins, J.L., Pilling, L.C., Heales, C.J., Savage, S., Kuo, C.-L., Kuchel, G.A., Steffens, D.C., & Melzer, D. (2021). Hemochromatosis Mutations, Brain Iron Imaging, and Dementia in the UK Biobank Cohort. Journal of Alzheimer’s Disease, 79(3), 1203–1211. https://doi.org/10.3233/jad-201080

Bader, V., & Winklhofer, K.F. (2020). Mitochondria at the Interface between Neurodegeneration and Neuroinflammation. Seminars in Cell & Developmental Biology, 99, 163–171.

Bellou V, Belbasis L, Tzoulaki I, Middleton LT, Ioannidis JPA, Evangelou E. Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses. Alzheimers Dement 2017;13(4):406–18. doi: 10.1016/j.jalz.2016.07.152.

Benn, M., Nordestgaard, B.G., Tybjærg-Hansen, A. et al. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals. Diabetologia 63, 1151–1161 (2020). https://doi.org/10.1007/s00125-020-05124-5

Bermejo‐Pareja, F., del Ser, T., Valentí, M., de la Fuente, M., Bartolome, F. and Carro, E., 2020. Salivary lactoferrin as biomarker for Alzheimer’s disease: Brain‐immunity interactions. Alzheimer’s & Dementia, [online] 16(8), pp.1196–1204. https://doi.org/10.1002/alz.12107.

Carro, E., Bartolomé, F., Bermejo-Pareja, F., Villarejo-Galende, A., Molina, J. A., Ortiz, P., Calero, M., Rabano, A., Cantero, J. L., & Orive, G. (2017). Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 8, 131-138. https://doi.org/10.1016/j.dadm.2017.04.002

Cerasuolo, M., Di Meo, I., Auriemma, M.C., Trojsi, F., Maiorino, M.I., Cirillo, M., Esposito, F., Polito, R., Colangelo, A.M., Paolisso, G., Papa, M., & Rizzo, M.R. (2023). Iron and Ferroptosis More than a Suspect: Beyond the Most Common Mechanisms of Neurodegeneration for New Therapeutic Approaches to Cognitive Decline and Dementia. International Journal of Molecular Sciences, 24(11), 9637. https://doi.org/10.3390/ijms24119637

Crane, P.K., Walker, R., Hubbard, R.A., Li, G., Nathan, D.M., Zheng, H., Haneuse, S., Craft, S., Montine, T.J., Kahn, S.E., McCormick, W., McCurry, S.M., Bowen, J.D. and Larson, E.B., 2013. Glucose Levels and Risk of Dementia. New England Journal of Medicine, [online] 369(6), pp.540–548. https://doi.org/10.1056/nejmoa1215740.

Cunnane, S.C., Courchesne‐Loyer, A., St‐Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., Croteau, E. and Castellano, C., 2016. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Annals of the New York Academy of Sciences, [online] 1367(1), pp.12–20. https://doi.org/10.1111/nyas.12999.

Davis, J.J., Fournakis, N., & Ellison, J. (2020). Ketogenic Diet for the Treatment and Prevention of Dementia: A Review. Journal of Geriatric Psychiatry and Neurology. https://doi.org/10.1177/0891988720901785

Daulatzai, M.A., 2016. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. Journal of Neuroscience Research, [online] 95(4), pp.943–972. https://doi.org/10.1002/jnr.23777.

Dineley, K. T., Jahrling, J. B., & Denner, L. (2014). Insulin Resistance in Alzheimer's Disease. Neurobiology of Disease, 72PA, 92. https://doi.org/10.1016/j.nbd.2014.09.001

DiNicolantonio, J.J., Mangan, D. and O’Keefe, J.H., 2018. The fructose–copper connection: Added sugars induce fatty liver and insulin resistance via copperdeficiency. Journal of Metabolic Health, [online] 3(1). https://doi.org/10.4102/jir.v3i1.43.

Dugger, B.N., & Dickson, D.W. (2017). Pathology of Neurodegenerative Diseases. In Cold Spring Harbor Perspectives in Biology. Cold Spring Harbor Laboratory Press.

Fiest KM, Jetté N, Roberts JI, et al. The prevalence and incidence of dementia: A systematic review and meta-analysis. Can J Neurol Sci 2016;43 Suppl 1:S3–50. doi: 10.1017/cjn.2016.18.

Gammella, E., Recalcati, S., & Cairo, G. (2016). Dual role of ROS as signal and stress agents: iron tips the balance in favor of toxic effects. Oxidative Medicine and Cellular Longevity, 2016(1), 8629024.

Garrett, L. R., & Niccoli, T. (2022). Frontotemporal Dementia and Glucose Metabolism. Frontiers in Neuroscience, 16, 812222. https://doi.org/10.3389/fnins.2022.812222

González-Reyes RE, Aliev G, Ávila-Rodrigues M, Barreto GE. Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. Curr Pharm Des. 2016;22(7):812-8. doi: 10.2174/1381612822666151209152013. PMID: 26648470.

Gorelick, P.B., Scuteri, A., Black, S.E., DeCarli, C., Greenberg, S.M., Iadecola, C., Launer, L.J., Laurent, S., Lopez, O.L., Nyenhuis, D., Petersen, R.C., Schneider, J.A., Tzourio, C., Arnett, D.K., Bennett, D.A., Chui, H.C., Higashida, R.T., Lindquist, R., Nilsson, P.M., Roman, G.C., Sellke, F.W. and Seshadri, S., 2011. Vascular Contributions to Cognitive Impairment and Dementia. Stroke, [online] 42(9), pp.2672–2713. https://doi.org/10.1161/str.0b013e3182299496.

Grammatikopoulou, M.G., Goulis, D.G., Gkiouras, K., Theodoridis, X., Gkouskou, K.K., Evangeliou, A., Dardiotis, E., & Bogdanos, D.P. (2020). To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. Advances in Nutrition, 11(6), 1583–1602. https://doi.org/10.1093/advances/nmaa073

Hertz, L., Chen, Y. and Waagepetersen, H.S., 2015. Effects of ketone bodies in Alzheimer’s disease in relation to neural hypometabolism, β‐amyloid toxicity, and astrocyte function. Journal of Neurochemistry, [online] 134(1), pp.7–20. https://doi.org/10.1111/jnc.13107.

Huo, T., Jia, Y., Yin, C., Luo, X., Zhao, J., Wang, Z., & Lv, P. (2019). Iron dysregulation in vascular dementia: Focused on the AMPK/autophagy pathway. Brain Research Bulletin, 153, 305–313. https://doi.org/10.1016/j.brainresbull.2019.09.006

Kalaria, R. N. (2018). The pathology and pathophysiology of vascular dementia. Neuropharmacology, 134, 226-239. https://doi.org/10.1016/j.neuropharm.2017.12.030

Krikorian, R., Shidler, M. D., Dangelo, K., Couch, S. C., Benoit, S. C., & Clegg, D. J. (2012). Dietary ketosis enhances memory in mild cognitive impairment. Neurobiology of Aging, 33(2), 425.e19. https://doi.org/10.1016/j.neurobiolaging.2010.10.006

Listabarth, S., König, D., Vyssoki, B. and Hametner, S., 2020. Does thiamine protect the brain from iron overload and alcohol‐related dementia? Alzheimer’s & Dementia, [online] 16(11), pp.1591–1595. https://doi.org/10.1002/alz.12146.

Magaki, S., Raghavan, R., Mueller, C., Oberg, K.C., Vinters, H.V., & Kirsch, W.M. (2007). Iron, copper, and iron regulatory protein 2 in Alzheimer’s disease and related dementias. Neuroscience Letters, 418(1), 72–76. https://doi.org/10.1016/j.neulet.2007.02.077

Mohamed, W. A., Salama, R. M., & Schaalan, M. F. (2019). A pilot study on the effect of lactoferrin on Alzheimer’s disease pathological sequelae: Impact of the p-Akt/PTEN pathway. Biomedicine & Pharmacotherapy, 111, 714-723. https://doi.org/10.1016/j.biopha.2018.12.118

Moon, Y., Han, S.-H., & Moon, W.-J. (2016). Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer’s Dementia Using Quantitative Susceptibility Mapping Imaging. Journal of Alzheimer’s Disease, 51(3), 737–745. https://doi.org/10.3233/jad-151037

Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S. and Kiyohara, Y., 2011. Glucose tolerance status and risk of dementia in the community. Neurology, [online] 77(12), pp.1126–1134. https://doi.org/10.1212/wnl.0b013e31822f0435.

Peloso GM, Beiser AS, Satizabal CL, et al. Cardiovascular health, genetic risk, and risk of dementia in the Framingham Heart Study. Neurology 2020;95(10):e1341–50. doi: 10.1212/WNL.0000000000010306.

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013;9(1):63–75.e2. doi: 10.1016/j.jalz.2012.11.007.

Raha, A.A., Biswas, A., Henderson, J., Chakraborty, S., Holland, A., Friedland, R.P., Mukaetova-Ladinska, E., Zaman, S. and Raha-Chowdhury, R., 2022. Interplay of Ferritin Accumulation and Ferroportin Loss in Ageing Brain: Implication for Protein Aggregation in Down Syndrome Dementia, Alzheimer’s, and Parkinson’s Diseases. International Journal of Molecular Sciences, [online] 23(3), p.1060. https://doi.org/10.3390/ijms23031060.

Rawlings, A.M., Sharrett, A.R., Mosley, T.H., Ballew, S.H., Deal, J.A. and Selvin, E., 2017. Glucose Peaks and the Risk of Dementia and 20-Year Cognitive Decline. Diabetes Care, [online] 40(7), pp.879–886. https://doi.org/10.2337/dc16-2203.

Roubroeks, J.A.Y., Smith, R.G., van den Hove, D.L.A., & Lunnon, K. (2017). Epigenetics and DNA Methylomic Profiling in Alzheimer’s Disease and Other Neurodegenerative Diseases. Journal of Neurochemistry, 143, 158–170.

Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev 2018;40:4–16. doi: 10.1016/j.smrv.2017.06.010.

Siah, C. W., Ombiga, J., Adams, L. A., Trinder, D., & Olynyk, J. K. (2006). Normal Iron Metabolism and the Pathophysiology of Iron Overload Disorders. Clinical Biochemist Reviews, 27(1), 5-16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1390789/

Wands, J. R. (2008). Alzheimer's Disease Is Type 3 Diabetes–Evidence Reviewed. Journal of Diabetes Science and Technology (Online), 2(6), 1101-1113. https://doi.org/10.1177/193229680800200619

Wu, C., Shapiro, L., Ouk, M., MacIntosh, B. J., Black, S. E., Shah, B. R., & Swardfager, W. (2022). Glucose-lowering drugs, cognition, and dementia: The clinical evidence. Neuroscience & Biobehavioral Reviews, 137, 104654. https://doi.org/10.1016/j.neubiorev.2022.104654

Zhao, Z. (2019). Iron and oxidizing species in oxidative stress and Alzheimer’s disease. Aging Medicine, 2(2), 82–87. https://doi.org/10.1002/agm2.12074

[covid-safer-hotties]

Published March 2, 2023

Neurodegenerative diseases, which include conditions such as Alzheimer disease (AD) Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), vascular dementia and multiple sclerosis (MS), are a class of progressive disorders defined by neuronal death. Each of these disorders is characterized by degeneration of distinct brain areas, and they present with overlapping but discrete symptoms that can include motor impairment, cognitive dysfunction, affective changes and/or dementia. With the exception of rare familial cases, the aetiopathogenic origins of these diseases are poorly understood; however, two common factors seem to be neuroinflammation and epidemiological links to viral infections1.

Neuroinflammation was originally thought to be a consequence of neurodegeneration; however, subsequent research indicated that neuroinflammation can drive the onset and progression of neurodegenerative diseases. The idea of neuroinflammation as a driver of neurodegeneration was advanced by genome-wide association studies (GWAS) that identified immune-related genes, including CD33 and TREM2, as risk factors for AD2. In addition, the ε4 allele of the apolipoprotein E gene (APOE ε4), which is the strongest known genetic risk factor for AD and accounts for approximately 10–20% of the risk of late-onset disease, has been hypothesized to exert its effects partially through neuroinflammatory processes3. These genetic factors increase the risk of developing neurodegenerative disease but are not sufficient to cause disease on their own. Instead, genetic risk factors are likely to work with environmental factors that underlie sporadic forms of neurodegenerative disease.

For the full article and a link to the study, check out the official Covid Safe Hotties archive:

[oldswarnaviharoldage]

Comprehensive Dementia Care in Pune: A Guide to Swarnavihar Old Age Homes

As the number of elderly individuals affected by dementia continues to rise, finding a reliable and compassionate care facility becomes crucial. In Pune, Swarnavihar Old Age Homes is recognized for offering specialized care for dementia patients, providing them with the support and environment they need to lead a dignified life. In this blog, we’ll explore what dementia care entails and why Swarnavihar is an excellent choice for dementia care in Pune.

Understanding Dementia and Its Challenges

Dementia is a term that covers a range of conditions associated with cognitive decline, impacting memory, thinking, behavior, and the ability to perform everyday activities. Alzheimer’s disease is the most common form of dementia, but there are many others like vascular dementia, Lewy body dementia, and frontotemporal dementia. These conditions make it increasingly difficult for individuals to function independently, requiring specialized care and support.

Key Challenges in Dementia Care:

Memory Loss: As dementia progresses, memory loss becomes more severe, affecting daily life and relationships.

Confusion and Disorientation: Patients often experience confusion about time, place, and even familiar people.

Mood and Behavior Changes: Emotional instability, aggression, and anxiety are common symptoms that need careful management.

Loss of Independence: Simple tasks like bathing, dressing, and eating can become difficult, requiring constant support.

These challenges mean that dementia care requires more than just medical attention. It demands a holistic approach that addresses physical, emotional, and social needs. This is where Swarnavihar Old Age Homes in Pune steps in.

Swarnavihar Old Age Homes: Compassionate Dementia Care in Pune

Swarnavihar is one of Pune’s leading care homes, providing a nurturing environment specifically designed to meet the needs of dementia patients. With its combination of experienced caregivers, a supportive community, and a well-structured routine, Swarnavihar ensures that residents live with dignity and comfort.

What Makes Swarnavihar a Great Choice for Dementia Care?

Specialized Care for Dementia: Swarnavihar understands that dementia care is a specialized field. The staff is trained to deal with the cognitive and emotional complexities of dementia, ensuring that patients receive the attention and care they deserve. This includes assistance with daily activities, administering medication, and offering emotional support.

Safe and Secure Environment: One of the main concerns for dementia patients is safety. Swarnavihar provides a secure environment with measures in place to prevent wandering, which is a common risk in dementia patients. The facility ensures that residents can move around freely while remaining safe.

Personalized Care Plans: Every dementia patient has unique needs. At Swarnavihar, individualized care plans are developed for each resident, addressing their specific medical and emotional requirements. This personalized approach ensures that patients receive care tailored to their condition, allowing them to live more comfortably.

Holistic Well-being: At Swarnavihar, dementia care goes beyond just managing the disease. The team focuses on enhancing the quality of life by encouraging social interaction, physical activities, and mental stimulation. This holistic approach helps improve mood and reduces the sense of isolation, which is common among dementia patients.

Emotional and Psychological Support: Dementia not only affects the patient but also their families. Swarnavihar offers counseling and emotional support to family members, helping them cope with the emotional strain of seeing a loved one struggle with dementia.

Medical Supervision and Assistance: With on-site healthcare professionals, Swarnavihar ensures that medical care is available 24/7. Regular health check-ups and emergency medical care are part of the comprehensive services offered, giving families peace of mind that their loved ones are in good hands.

Engagement and Activity Programs: To maintain cognitive function and improve the emotional well-being of residents, Swarnavihar offers a variety of activities designed specifically for dementia patients. These include memory games, music therapy, art sessions, and light physical exercises that promote mental and physical engagement.

Why Pune is an Ideal Location for Dementia Care

Pune, known for its pleasant climate and peaceful surroundings, is an ideal city for elderly care, including dementia care. The serene environment provides a calming backdrop for those suffering from cognitive decline. Swarnavihar Old Age Homes, located in Pune, takes full advantage of the city’s tranquil ambiance to offer a soothing atmosphere for its residents.

Moreover, Pune has a growing healthcare infrastructure, ensuring that advanced medical facilities are always within reach. This makes it easier for care homes like Swarnavihar to collaborate with hospitals and specialists when needed, ensuring that residents have access to comprehensive medical care.

Choosing the Right Dementia Care Facility in Pune

When selecting a dementia care home in Pune, it’s essential to consider the facility’s approach to care, the qualifications of the staff, and the overall environment. Swarnavihar Old Age Homes excels in all these areas, offering a compassionate and professional care setting designed specifically for dementia patients.

Key Considerations When Choosing Dementia Care:

Trained Staff: Ensure the staff is trained to handle dementia-related challenges and is compassionate toward the residents.

Safety Measures: Look for a secure environment that prevents wandering and ensures the safety of residents.

Emotional Support: Choose a facility that offers both medical and emotional care, supporting not just the patient but also their family.

Holistic Approach: A good care home will focus on both mental and physical well-being, offering activities that stimulate the mind and body.

Conclusion: Caring for Dementia Patients with Dignity

Caring for someone with dementia can be emotionally challenging, but choosing the right care facility can make a significant difference in the patient’s quality of life. Swarnavihar Old Age Homes in Pune provides a compassionate, secure, and professional environment where dementia patients can thrive.

Visit us https://swarnaviharoldagehomes.com/service/dementia-care-in-pune/ 

[goinstacare]

Navigating Alzheimer’s and Dementia Care: Essential Support for Individuals and Families

 Alzheimer’s disease and other forms of dementia pose significant challenges for both individuals and their families. As these conditions progressively impact memory, cognition, and daily functioning, specialized care becomes crucial to ensure the best possible quality of life. Understanding Alzheimer’s and dementia care is key to providing effective support and managing the unique needs associated with these conditions.

What are Alzheimer’s and Dementia?

Alzheimer’s Disease: Alzheimer’s is the most common form of dementia, characterized by progressive memory loss, cognitive decline, and changes in behavior and personality. It involves the buildup of amyloid plaques and tau tangles in the brain, which disrupt normal brain function.

Dementia: Dementia is an umbrella term for a range of symptoms affecting memory, thinking, and reasoning. Alzheimer’s disease is a type of dementia, but other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Each type has distinct characteristics but shares common challenges related to cognitive decline.

Core Principles of Alzheimer’s and Dementia Care

Person-Centered Care: This approach focuses on understanding and respecting the individual’s preferences, needs, and life history. It involves tailoring care strategies to the person’s unique experiences and abilities, promoting dignity and individuality.

Safety and Security: As cognitive abilities decline, ensuring a safe environment becomes critical. This includes making modifications to the living space to prevent accidents, monitoring for wandering, and addressing any potential safety hazards.

Effective Communication: Communication strategies should be adapted to the individual’s abilities. Simple, clear instructions and a calm, reassuring tone can help reduce confusion and frustration. Non-verbal communication, such as gestures and facial expressions, also plays a crucial role.

Emotional Support: Individuals with dementia may experience a range of emotions, including confusion, frustration, and anxiety. Providing emotional support through companionship, reassurance, and understanding can help alleviate distress and improve overall well-being.

Structured Routine: Establishing a consistent daily routine helps individuals with dementia feel more secure and less anxious. Predictable activities and schedules can reduce confusion and provide a sense of stability.

Key Services in Alzheimer’s and Dementia Care

Medical Management: Medical care for individuals with dementia focuses on managing symptoms, addressing coexisting health conditions, and monitoring medication. This may involve consultations with neurologists, geriatricians, or other specialists.

Memory Care: Specialized memory care units or facilities offer tailored environments designed to meet the needs of individuals with advanced dementia. These settings provide structured activities, secure environments, and staff trained in dementia care.

Personal Care: Assistance with daily living activities, such as bathing, dressing, eating, and grooming, is crucial for individuals with dementia. Personal care services aim to maintain comfort and dignity while ensuring that individual needs are met.

Behavioral Support: Addressing challenging behaviors associated with dementia, such as aggression, agitation, or withdrawal, requires specialized techniques and interventions. Behavioral support involves creating individualized strategies to manage and mitigate these behaviors.

Family Support and Education: Caregivers and family members play a vital role in supporting individuals with dementia. Educational resources, support groups, and counseling services can help families understand the disease, cope with caregiving challenges, and access additional support.

Where to Find Alzheimer’s and Dementia Care Services

Memory Care Facilities: These specialized facilities offer comprehensive care for individuals with dementia, including secure environments, structured programs, and trained staff. Memory care units are often part of assisted living communities or nursing homes.

In-Home Care Services: In-home care provides personalized support within the individual’s own home. Services may include personal care assistance, companionship, and respite care for family caregivers.

Adult Day Care Programs: These programs offer daytime care and activities for individuals with dementia, allowing caregivers to take a break while ensuring their loved one engages in social and recreational activities.

Hospitals and Clinics: Many hospitals and clinics have dedicated dementia care programs or departments that provide medical management, diagnostic services, and treatment options.

How to Access Alzheimer’s and Dementia Care

Consult with Healthcare Providers: Start by discussing care needs with the individual’s primary care physician or a specialist in dementia care. They can provide recommendations, referrals, and information on available services.

Research Local Resources: Look for local organizations, support groups, and agencies that specialize in Alzheimer’s and dementia care. Many communities offer resources and services tailored to these conditions.

Evaluate Care Options: Consider the individual’s specific needs and preferences when evaluating care options. Visiting facilities, interviewing caregivers, and understanding service offerings can help in making informed decisions.

Understand Financial Considerations: Explore insurance coverage, government programs, and financial assistance options to help manage the costs of care. Some services may be covered by Medicare, Medicaid, or private insurance.

Conclusion

Alzheimer’s and dementia care require a compassionate, individualized approach to address the unique challenges associated with these conditions. By focusing on person-centered care, safety, effective communication, and emotional support, caregivers and healthcare professionals can enhance the quality of life for individuals with dementia. If you or a loved one is facing Alzheimer’s disease or another form of dementia, exploring available care options and resources can help ensure a supportive and fulfilling experience during this journey.